TP53 and Barrett esophagus: Di Pietro M et al. also reported that a three-biomarker panel, composed of aneuploidy, p53 immunohistochemistry, and cyclin A, provided accurate and objective diagnosis of dysplasia in BE patients with a small number of targeted biopsies conducted in an AFI-positive area [108].